Fractyl has the GUTS: Obe­si­ty and di­a­betes biotech charts $99M IPO

Fractyl Health is at­tempt­ing to ride the waves cre­at­ed by last week’s suc­cess­ful biotech IPOs for can­cer drug­mak­ers CG On­col­o­gy and Ar­riVent Bio­phar­ma.

The car­diometa­bol­ic biotech said Mon­day morn­ing it ex­pects about $99 mil­lion in net pro­ceeds from its Nas­daq de­but, like­ly to oc­cur lat­er this week. That haul would come if the Mass­a­chu­setts biotech prices at the mid­point of a pro­posed $14 to $16 range by sell­ing 7.33 mil­lion shares as $GUTS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER